Cytokine Dynamics in Bortezomib-Induced Peripheral Neuropathy: Challenges in Translating Preclinical Findings to Humans.

ABSTRACT:

Background and aims

Bortezomib-induced peripheral neuropathy (BIPN) remains a common treatment side effect in patients with multiple myeloma (MM). Data from rodent models indicate a role of proinflammatory cytokines in BIPN pathophysiology, making them potential therapeutic targets. We therefore tested cytokine levels throughout the course of BIPN in a cohort of MM patients.

Methods

We performed an interim analysis of a monocentric, non-randomized, observational study including 113 patients with MM. Three groups of patients-within their first cycle of BTZ treatment (FC), with ongoing BTZ treatment at the time of recruiting (OT), and with BTZ treatment in the past (PT)-were compared to controls. Sixteen FC patients were followed up for a median of 6 months. Serum TNF-α, IL-6,

SUBMITTER: Cebulla N 

PROVIDER: S-EPMC12831098 | biostudies-literature | 2026 Mar

REPOSITORIES: biostudies-literature